Results 81 to 90 of about 7,229 (203)

Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV

, 2023
Objectives: We aimed to investigate and compare the efficacy and safety of two dolutegravir-based two-drug regimens: dolutegravir + lamivudine versus dolutegravir + rilpivirine.
Lagi, F, Iannone, V, Baldin, G, Di Giambenedetto, S, Ciccullo, A, Borghi, V, Antinori, S, Mussini, C, Capetti, A, Sterrantino, G, Giacomelli, A, Cossu, M V, Farinacci, D, Passerotto, R A   +13 more
core   +1 more source

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review

Viruses
The use of long-acting cabotegravir and rilpivirine (LA CAB/RPV) is a novel approach to manage human immunodeficiency virus (HIV). This injectable regimen offers benefits such as an improved quality of life, reduced stigma and enhanced treatment ...
Martina Bottanelli, Antonella Castagna, Camilla Muccini   +2 more
doaj   +1 more source

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Viruses, 2015
At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population ...
Danielle P. Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen, Michael D. Miller, Kirsten L. White   +7 more
doaj   +1 more source

Rilpivirine [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States

Journal of the International AIDS Society
Introduction Long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) represents a breakthrough in HIV treatment. However, understanding how to optimize real‐world service delivery and user experiences among people with HIV (PWH) remains limited ...
Xavier A. Erguera, Mollie B. Smith, Priyasha Pareek, Alicia Dawdani, Kaylin V. Dance, Ryan S. Walker, Janet Grochowski, Jon Oskarsson, Matthew D. Hickey, Mallory O. Johnson, John Sauceda, Jose I. Gutierrez Jr., Elizabeth T. Montgomery, Jonathan A. Colasanti, Lauren F. Collins, Moira C. McNulty, Kimberly A. Koester, Katerina A. Christopoulos   +17 more
doaj   +1 more source

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy

Aims: Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically-based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in ...
Atoyebi, Shakir, Olagunju, Adeniyi, Montanha, Maiara, Waitt, Catriona, Grañana-Castillo, Sandra, Cottura, Nicolas, Bunglawala, Fazila, Siccardi, Marco   +7 more
core   +1 more source

The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections

Viruses
Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections.
Erik De Clercq
doaj   +1 more source

DEVELOPMENT & VALIDATION OF STABILITY INDICATING HPTLC METHOD FOR RILPIVIRINE & DOLUTEGRAVIR SODIUM IN COMBINATION

, 2017
Objective: To develop and validate stability indicating HPTLC method for determination of Rilpivirine and Dolutegravir Sodium Methods: The chromatographic development was carried out on aluminum plates pre-coated with silica gel 60 F254 as stationary ...
Mrinalini C. Damle*, Amita N. Pardeshi
core   +1 more source

Pharmacokinetic and pharmacodynamic modeling of rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir disoproxil fumarate/emtricitabine

, 2019
La rilpivirine est une molécule très prescrite dont les relations pharmacocinétique-pharmacodynamique n’avaient jamais été caractérisées en conditions cliniques réelles lors de l’initiation de ce travail.
Néant, Nadège
core  

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

, 2018
Background Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor-resistant HIV-
Chanson J Brumme, Kerri J Penrose, Kelley Gordon, Maritsa Scoulos-Hanson, John W Mellors, Kristen Hamanishi, Raquel V Viana, Carole L Wallis, P Richard Harrigan, Urvi M Parikh   +9 more
core   +1 more source